VYGR Latest Press Releases

-- October 27, 2026 --

Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 Globe Newswire 8:01 AM

-- October 21, 2026 --

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President Globe Newswire 8:01 AM

-- September 1, 2026 --

Voyager to Present at Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 6, 2026 --

Voyager Reports Second Quarter 2026 Financial and Operating Results Globe Newswire 4:01 PM

-- July 13, 2026 --

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 Globe Newswire 8:01 AM

-- June 29, 2026 --

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 Globe Newswire 8:01 AM

-- June 11, 2026 --

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes